Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NICHOLAS P MARTINEZ

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1174843726
CMS profile
1388246
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,395.77

81 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NICHOLAS P MARTINEZ

NPI 1174843726 · CMS profile ID 1388246

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174843726?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NICHOLAS P MARTINEZ, NPI 1174843726, CMS profile ID 1388246. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174843726?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). NICHOLAS P MARTINEZ, NPI 1174843726, CMS profile ID 1388246. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174843726?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
NICHOLAS P MARTINEZ, NPI 1174843726, CMS profile ID 1388246, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1174843726?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

81 matching records · $1,395.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 81 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–81 of 81.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.1705/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959452139 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.7505/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959893471 CMS
RedHill Biopharma Inc. $16.2804/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902949601 CMS
ABBVIE INC. $16.5004/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107657 CMS
ABBVIE INC. $1.3903/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107651 CMS
ABBVIE INC. $26.4003/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107653 CMS
ABBVIE INC. $4.0403/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107655 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.5903/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959589527 CMS
RedHill Biopharma Inc. $16.6203/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902945307 CMS
ABBVIE INC. $13.8603/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107649 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.2203/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959557959 CMS
Amgen Inc. $18.8303/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939411229 CMS
ABBVIE INC. $16.8203/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107645 CMS
ABBVIE INC. $8.4803/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107647 CMS
ABBVIE INC. $25.6802/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107643 CMS
Janssen Biotech, Inc. $12.7402/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886657077 CMS
Braintree Laboratories, Inc. $11.7402/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898419011 CMS
ABBVIE INC. $15.1802/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107641 CMS
ABBVIE INC. $11.6602/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107639 CMS
ABBVIE INC. $8.0201/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107637 CMS
Janssen Biotech, Inc. $4.1701/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886657071 CMS
ABBVIE INC. $12.8001/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107635 CMS
Janssen Biotech, Inc. $11.2601/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886657065 CMS
Janssen Biotech, Inc. $2.4401/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886657135 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.7201/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959591707 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.2301/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955719499 CMS
Janssen Biotech, Inc. $2.0801/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886657129 CMS
ABBVIE INC. $15.3101/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107633 CMS
ABBVIE INC. $17.5001/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107631 CMS
Janssen Biotech, Inc. $2.7601/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886657053 CMS
Janssen Biotech, Inc. $9.3801/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886657059 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,675.91 98
PY2020 $967.47 50
PY2021 $13,132.96 69
PY2022 $1,395.77 81
PY2023 $1,087.13 57
PY2024 $39,294.82 115
PY2025 $1,532.42 80

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $359,824.21 13
PY2024 Principal investigator $198,332.16 36
PY2023 Recipient $976.70 1
PY2023 Principal investigator $249,380.12 9
PY2022 Principal investigator $195,461.50 6
PY2021 Recipient $18,696.71 3
PY2021 Principal investigator $167,161.72 6
PY2020 Recipient $15,023.48 3
PY2020 Principal investigator $213,912.03 12
PY2019 Recipient $31,119.42 4
PY2019 Principal investigator $176,055.93 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

13 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,713.30 11/04/2025 Non-covered Recipient Entity
Gastroenterology Research of America, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040955
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,970.20 09/25/2025 Non-covered Recipient Entity
Gastroenterology Research of America, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040953
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,012.80 09/09/2025 Non-covered Recipient Entity
Gastroenterology Research of America, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040951
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,405.40 07/10/2025 Non-covered Recipient Entity
Gastroenterology Research of America, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040949
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,916.40 06/03/2025 Non-covered Recipient Entity
Gastroenterology Research of America, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040947
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $26,925.30 05/13/2025 Non-covered Recipient Entity
Gastroenterology Research of America, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040945
Principal investigator 1 Phathom Pharmaceuticals, Inc. $10,500.00 05/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF A
EoE-201 No dispute reported 06/30/2026 1224868894
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $34,191.00 04/29/2025 Non-covered Recipient Entity
Gastroenterology Research of America, LLC
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) No dispute reported 06/30/2026 1244040929
Principal investigator 1 Eli Lilly and Company $108,548.11 03/26/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CLINIC OF SAN ANTONIO
AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187883490
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $28,184.40 03/13/2025 Non-covered Recipient Entity
Gastroenterology Research of America, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040943
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,603.20 03/11/2025 Non-covered Recipient Entity
Gastroenterology Research of America, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040941
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $56,059.20 01/23/2025 Non-covered Recipient Entity
Gastroenterology Research of America, LLC
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) No dispute reported 06/30/2026 1244040927
Principal investigator 1 Eli Lilly and Company $43,794.90 01/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CLINIC OF SAN ANTONIO
A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB No dispute reported 06/30/2026 1187881108